Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche. The most common side effects include the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach, rash, joint pain, extremity pain, fatigue and nausea. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - Satralizumab (de)
- Satralizumab (en)
|
rdfs:comment
| - Satralizumab (Handelsname: Enspryng) ist ein Arzneistoff, der zur Behandlung von Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) zugelassen ist. Der humanisierte monoklonaler Antikörper bindet an den Rezeptor von Interleukin-6 und blockiert dadurch die von diesem Zytokin vermittelten Entzündungsprozesse und verlängert damit den Zeitraum zwischen Erkrankungsschüben. (de)
- Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche. The most common side effects include the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach, rash, joint pain, extremity pain, fatigue and nausea. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en)
|
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
ATC suffix
| |
ATC prefix
| |
c
| |
CAS number
| |
DrugBank
| |
H
| |
KEGG
| |
legal status
| |
legal US
| |
n
| |
O
| |
routes of administration
| |
s
| |
source
| |
synonyms
| - SA-237, sapelizumab, satralizumab-mwge (en)
|
target
| |
tradename
| |
type
| |
UNII
| |
has abstract
| - Satralizumab (Handelsname: Enspryng) ist ein Arzneistoff, der zur Behandlung von Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) zugelassen ist. Der humanisierte monoklonaler Antikörper bindet an den Rezeptor von Interleukin-6 und blockiert dadurch die von diesem Zytokin vermittelten Entzündungsprozesse und verlängert damit den Zeitraum zwischen Erkrankungsschüben. (de)
- Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche. The most common side effects include the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach, rash, joint pain, extremity pain, fatigue and nausea. Satralizumab regulates inflammation by inhibiting the interleukin-6 (IL-6) receptor, a key mediator of the immune response. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en)
|
DailyMedID
| |
legal AU
| |
legal CA
| - Rx-only / Schedule D (en)
|
licence CA
| |
mab type
| |
pregnancy AU
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
alternative name
| |
CAS number
| |
DrugBank
| |
FDA UNII code
| |
KEGG
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is Wikipage redirect
of | |
is medication
of | |
is foaf:primaryTopic
of | |